Author [ Title] Type Year
Filters: Author is Kim, Haesook T [Clear All Filters]
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.
Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin. Biol Blood Marrow Transplant. 2019..
Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021;37(6):109992.
Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest. 2020.